L. Todd Edwards serves as the Chief Commercial Officer at Arcutis Biotherapeutics Inc., a position he has held since joining the company in 2020. With over two decades of experience in the biopharmaceutical industry, Edwards has a proven track record of successfully launching and commercializing innovative therapies across various therapeutic areas. Prior to Arcutis, he held leadership roles at several prominent companies, including Amgen, where he served as Vice President and General Manager of the Biosimilars business unit, and Genentech, where he was the head of the Immunology business unit. At Arcutis Biotherapeutics, Edwards is responsible for overseeing the company's commercial strategy and operations, which includes building and leading a high-performing commercial team. His role is pivotal in driving the successful launch and market penetration of Arcutis' novel dermatology therapies, such as the company's lead product, ZORYVE (roflumilast) cream, which is approved for the treatment of plaque psoriasis. Edwards' strategic vision and deep understanding of the dermatology market have been instrumental in positioning Arcutis as a leader in the development of innovative treatments for immune-mediated dermatological diseases. Throughout his career, Edwards has demonstrated a strong commitment to improving patient outcomes and advancing the field of biopharmaceuticals. He has been recognized for his leadership and contributions to the industry, receiving numerous awards and accolades. Edwards holds a Bachelor of Science degree in Business Administration from the University of Southern California and an MBA from the UCLA Anderson School of Management. His expertise, coupled with his passion for developing transformative therapies, continues to drive Arcutis Biotherapeutics' mission to address the unmet needs of patients with dermatological conditions.